Sanguine Diagnostics and Therapeutics
Publicly observedOmaha, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Omaha | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Sanguine Diagnostics and Therapeutics | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ECGMLSHGH4X6 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2026Publicly observed
NIH SBIR/STTR award: Anti-MUC16 humanized antibody combination regimen for targeting metastasis in pancreatic cancer
USD 399,999.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.